BR112022009396A2 - Análogos de incretina e usos dos mesmos - Google Patents
Análogos de incretina e usos dos mesmosInfo
- Publication number
- BR112022009396A2 BR112022009396A2 BR112022009396A BR112022009396A BR112022009396A2 BR 112022009396 A2 BR112022009396 A2 BR 112022009396A2 BR 112022009396 A BR112022009396 A BR 112022009396A BR 112022009396 A BR112022009396 A BR 112022009396A BR 112022009396 A2 BR112022009396 A2 BR 112022009396A2
- Authority
- BR
- Brazil
- Prior art keywords
- incretin
- glucagon
- receptors
- incretin analogs
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Details Of Garments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
ANÁLOGOS DE INCRETINA E USOS DOS MESMOS. A presente invenção refere-se a análogos de incretina que têm atividade em cada um dos receptores de polipeptídeo insulinotrópico dependente de glicose (GIP), peptídeo-1 semelhante ao glucagon (GLP-1) e glucagon (GCG). Os análogos de incretina têm características estruturais que resultam em atividade balanceada e duração de ação prolongada em cada um desses receptores. A invenção também se refere a métodos para tratar doenças tais como diabetes mellitus tipo 2, dislipidemia, síndrome metabólica, doença hepática gordurosa não alcoólica, esteato-hepatite não alcoólica e obesidade.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949661P | 2019-12-18 | 2019-12-18 | |
| PCT/US2020/064512 WO2021126695A1 (en) | 2019-12-18 | 2020-12-11 | Incretin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009396A2 true BR112022009396A2 (pt) | 2022-08-09 |
Family
ID=74181298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009396A BR112022009396A2 (pt) | 2019-12-18 | 2020-12-11 | Análogos de incretina e usos dos mesmos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230102339A1 (pt) |
| EP (1) | EP4077365A1 (pt) |
| JP (1) | JP7450724B2 (pt) |
| KR (1) | KR20220100676A (pt) |
| CN (1) | CN114787183A (pt) |
| AR (1) | AR120714A1 (pt) |
| AU (1) | AU2020408139B2 (pt) |
| BR (1) | BR112022009396A2 (pt) |
| CA (1) | CA3162245A1 (pt) |
| CL (1) | CL2022001623A1 (pt) |
| CO (1) | CO2022008264A2 (pt) |
| CR (1) | CR20220279A (pt) |
| DO (1) | DOP2022000122A (pt) |
| EC (1) | ECSP22048612A (pt) |
| IL (1) | IL293754A (pt) |
| JO (1) | JOP20220153A1 (pt) |
| MX (1) | MX2022007666A (pt) |
| PE (1) | PE20221518A1 (pt) |
| TW (1) | TWI795698B (pt) |
| WO (1) | WO2021126695A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023088140A1 (zh) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | 订合肽及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
| CA3015922A1 (en) | 2016-03-10 | 2017-09-14 | Medimmune Limited | Glucagon and glp-1 co-agonists for the treatment of obesity |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
-
2020
- 2020-12-10 AR ARP200103435A patent/AR120714A1/es unknown
- 2020-12-10 TW TW109143561A patent/TWI795698B/zh active
- 2020-12-11 JP JP2022537359A patent/JP7450724B2/ja active Active
- 2020-12-11 MX MX2022007666A patent/MX2022007666A/es unknown
- 2020-12-11 KR KR1020227020239A patent/KR20220100676A/ko active Search and Examination
- 2020-12-11 CA CA3162245A patent/CA3162245A1/en active Pending
- 2020-12-11 WO PCT/US2020/064512 patent/WO2021126695A1/en active Application Filing
- 2020-12-11 CN CN202080087802.4A patent/CN114787183A/zh active Pending
- 2020-12-11 PE PE2022001115A patent/PE20221518A1/es unknown
- 2020-12-11 EP EP20839440.3A patent/EP4077365A1/en active Pending
- 2020-12-11 CR CR20220279A patent/CR20220279A/es unknown
- 2020-12-11 IL IL293754A patent/IL293754A/en unknown
- 2020-12-11 AU AU2020408139A patent/AU2020408139B2/en active Active
- 2020-12-11 BR BR112022009396A patent/BR112022009396A2/pt unknown
- 2020-12-11 JO JOP/2022/0153A patent/JOP20220153A1/ar unknown
- 2020-12-11 US US17/785,758 patent/US20230102339A1/en active Pending
-
2022
- 2022-06-13 CO CONC2022/0008264A patent/CO2022008264A2/es unknown
- 2022-06-14 DO DO2022000122A patent/DOP2022000122A/es unknown
- 2022-06-15 CL CL2022001623A patent/CL2022001623A1/es unknown
- 2022-06-17 EC ECSENADI202248612A patent/ECSP22048612A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI795698B (zh) | 2023-03-11 |
| JP2023506952A (ja) | 2023-02-20 |
| CO2022008264A2 (es) | 2022-07-08 |
| AU2020408139B2 (en) | 2024-03-28 |
| AU2020408139A1 (en) | 2022-06-09 |
| EP4077365A1 (en) | 2022-10-26 |
| US20230102339A1 (en) | 2023-03-30 |
| MX2022007666A (es) | 2022-07-19 |
| CA3162245A1 (en) | 2021-06-24 |
| AR120714A1 (es) | 2022-03-09 |
| JOP20220153A1 (ar) | 2023-01-30 |
| KR20220100676A (ko) | 2022-07-15 |
| DOP2022000122A (es) | 2022-07-31 |
| IL293754A (en) | 2022-08-01 |
| CL2022001623A1 (es) | 2023-01-20 |
| WO2021126695A1 (en) | 2021-06-24 |
| TW202138385A (zh) | 2021-10-16 |
| ECSP22048612A (es) | 2022-07-29 |
| CR20220279A (es) | 2022-07-03 |
| JP7450724B2 (ja) | 2024-03-15 |
| PE20221518A1 (es) | 2022-10-04 |
| CN114787183A (zh) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091290A1 (ru) | Аналоги инкретина и их применение | |
| EA202091284A1 (ru) | Аналоги инкретина и их применение | |
| MY197569A (en) | Gip/glp1 co-agonist compounds | |
| BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
| EA202090392A3 (ru) | Соединения-коагонисты гип и гпп-1 | |
| BR112022009396A2 (pt) | Análogos de incretina e usos dos mesmos | |
| BR112022000027A2 (pt) | Compostos agonistas gipr | |
| PT3936142T (pt) | Agonista triplo com atividade em relação a todos os recetores de glucagon, glp-1 e gip para tratamento de doenças hepáticas | |
| BR112015003916A2 (pt) | peptídeo selecionado a partir do grupo consistindo no peptídeo glp-1, no peptídeo gip e seus análogos resistentes a dipeptidil-peptidase iv (dpp-iv); e composição farmacêutica | |
| CO2023012373A2 (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| BR112021017315A2 (pt) | Usos terapêuticos de dulaglutida | |
| EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 |